Approval · Notice of Compliance 38248 · 2026
MNEXSPIKE: Notice of Compliance 38248
Issued September 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38248
- Date
- September 9, 2026
- Company
- Moderna Biopharma Canada CorporationToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to antigen composition (Omicron XFG variant)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MNEXSPIKE | Not yet assigned | — |
Medicinal ingredients
- MRNA ENCODING SARS-COV-2 SPIKE PROTEIN NTD-RBD SUBDOMAINS 10 MCG per 0.2ML